key: cord-0739626-n84buos7
authors: Kagucia, E Wangeci; Gitonga, John N; Kalu, Catherine; Ochomo, Eric; Ochieng, Benard; Kuya, Nickline; Karani, Angela; Nyagwange, James; Karia, Boniface; Mugo, Daisy; Karanja, Henry K; Tuju, James; Mutiso, Agnes; Maroko, Hosea; Okubi, Lucy; Maitha, Eric; Ajuck, Hossan; Mukabi, David; Moracha, Wycliffe; Bulimu, David; Andanje, Nelson; Aman, Rashid; Mwangangi, Mercy; Amoth, Patrick; Kasera, Kadondi; Ng’ang’a, Wangari; Nyaguara, Amek; Voller, Shirine; Otiende, Mark; Bottomley, Christian; Agoti, Charles N; Ochola-Oyier, Lynette I; Adetifa, Ifedayo M O; Etyang, Anthony O; Gallagher, Katherine E; Uyoga, Sophie; Barasa, Edwine; Bejon, Philip; Tsofa, Benjamin; Agweyu, Ambrose; Warimwe, George M; Scott, J Anthony G
title: Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
date: 2021-06-12
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab314
sha: c0346c7e3095ac92b2b43785ebeb21c9452adeb4
doc_id: 739626
cord_uid: n84buos7

In October 2020, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G seroprevalence among truck drivers and their assistants (TDA) in Kenya was 42.3%, higher than among healthcare workers and blood donors. Truck drivers and their assistants transport essential supplies during the coronavirus disease 2019 pandemic, placing them at increased risk of being infected and of transmitting SARS-CoV-2 over a wide geographical area.

Serosurveillance for antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to estimate the cumulative incidence of SARS-CoV-2 infection. This is of particular interest among frontline workers, such as truck drivers, who are exempted from coronavirus disease 2019 (COVID-19) restrictions such as curfews and lockdowns.

Shortly after the first locally detected SARS-CoV-2 infection in March 2020, the Government of Kenya instituted containment measures, including travel restrictions. Freight transportation was excluded from travel restrictions because truckers and drivers' assistants (TDA) were deemed essential workers [1] . In May 2020, the Kenya Ministry of Health implemented mandatory bimonthly SARS-CoV-2 nucleic acid testing (NAT) for longdistance TDA, in line with East African Community guidelines [2, 3] . Although NAT data can be used to estimate the cumulative incidence of SARS-CoV-2 infection [4] , accurate estimates are dependent on the availability of reliable model parameter values.

There are currently no estimates of SARS-CoV-2 antibody seroprevalence among TDA globally. Due to the nature of their work, TDA interact with a wide variety of social and professional contacts over a large geographical area, putting them at increased risk of SARS-CoV-2 infection. We undertook a serosurvey to estimate the prevalence of SARS-CoV-2 antibodies among TDA in Kenya.

A cross-sectional serosurvey was conducted at 3 sites: 1 in Kilifi County in South-Eastern Kenya and 2 in Busia County in Western Kenya (Supplementary Figure 1) . In Kilifi County, TDA transporting salt domestically and to East African countries (eg, Uganda, Rwanda and Burundi) were engaged at salt harvesting companies located in Gongoni area, Magarini Sub-County. In Busia County, TDA were engaged at One Stop Border Posts (OSBPs) in 2 border towns, Busia and Malaba. Truckers and drivers' assistants at Busia OSBP and Malaba OSBP typically transport freight between Mombasa, Kenya and countries in East Africa (Supplementary Figure 2) .

Truckers and drivers' assistants were eligible if they were aged ≥18 years without a medical contraindication for blood sample collection. Participation was voluntary and verbal consent was sought before blood sample collection. Serosurveillance was conducted as a public health activity requested by the Kenya Ministry of Health, and ethical approval for publication of these data was obtained from the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085).

The study did not include factors necessitating patient consent.

Sociodemographic and clinical data, including age, sex, nationality, residence, temperature, and symptoms of illness within the previous 2 weeks, were collected by county public health staff (CPHS) and recorded on governmental COVID-19 surveillance forms (Supplementary Forms 1 and 2). Venous blood samples were collected using standard blood sample collection procedures and labeled with the same unique identifier as nasopharyngeal/oropharyngeal (NP/OP) samples. The NP/OP NAT results, linked using the unique identifiers, were obtained from testing laboratories. Data with personal identifiers were retained only by CPHS.

Plasma was extracted from blood samples using standard techniques and stored at −80°C before antibody testing. Thawed plasma samples were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) using a locally validated whole spike enzymelinked immunosorbent assay (ELISA) with 93% sensitivity and 99% specificity, as described previously [5, 6] . Spike ELISA positivity was defined as a ratio of sample optical density (OD) over negative control OD >2. The NP/OP NAT results are routinely provided to TDA by CPHS. Serology results were also provided to TDA by CPHS.

At least 700 samples were required to estimate seroprevalence as low as 2% within a 1% margin of error. Age was categorized into 10-year strata. Crude seroprevalence was estimated as the number of anti-SARS-CoV-2 IgG-positive samples (OD ratio >2) divided by all samples, and associated exact binomial 95% confidence intervals (CIs) were calculated. Bayesian adjustment for assay sensitivity and specificity was performed as previously described [6] . Associations between seropositivity and sociodemographic/clinical characteristics were tested using χ 2 or Fisher's exact tests. Test-performance-adjusted seroprevalence and credible intervals were calculated in R (version 3.6.1) with RStan. All other analyses were performed using Stata (version 15.1).

The serosurvey was conducted in Magarini between September 30 and October 23, 2020 and in Busia County on October 13-15, 2020. In total, 830 TDA (Busia OSBP n = 365; Magarini n = 101; Malaba OSBP n = 364) provided a blood sample, representing 52.4% of TDA approached (Supplementary Figure  3) . Of the 830 samples, 91.1% were collected between October 13 and 15, 2020 (Supplementary Figure 4) . The median age of sampled TDA was 40 years (interquartile range, 34-48 years) and 668 (80.5%) were Kenyan. Only 3 (0.4%) of the TDA were female (Table 1) . Among Kenyan TDA, reported county of residence included 31 of the country's 47 counties. The most common counties of residence were Mombasa, Uasin Gishu, and Nakuru (Supplementary Table 1 ). Driver versus assistant role was not recorded, but, on the basis of truck driver licensure age requirements, at least 53 (6.6%) were assistants (Table 1) .

Of 785 TDA with available NAT results, 58 (7.4%) were positive for SARS-CoV-2 (Table 1) ; positivity was significantly . Seroprevalence was highest in TDA <30 years of age and lowest among those aged ≥50 years. All 3 female TDA were seropositive for anti-SARS-CoV-2 IgG. Seroprevalence was 39.6% (95% CrI, 35.0−43.9) among TDA negative for SARS-CoV-2 by NAT and 59.0% (95% CrI, 46.0−72.1) among those with a positive SARS-CoV-2 NAT result. Seroprevalence among Kenyan TDA was comparable to that of other nationalities. By site, seroprevalence was highest at Busia OSBP and lowest at Malaba OSBP. Crude heterogeneity tests and uncertainty intervals for antibody test-adjusted estimates suggested no significant association between seroprevalence and age and significant differences in seroprevalence by site (Table 1 and Supplementary Table 3 ).

We estimate that approximately 4 in 10 TDA in Kenya had been infected with SARS-CoV-2 by late October 2020, as the country experienced the initial stages of a second pandemic wave (Supplementary Figure 5) . This study is notable for being the first to report SARS-CoV-2 seroprevalence among TDA.

Anti-SARS-CoV-2 IgG seroprevalence among TDA was more than 4-fold higher compared to average seroprevalence among Kenyan blood donors by September 2020 [7] and 2-fold higher compared to average seroprevalence in healthcare workers (HCWs) across 5 Kenyan health facilities by October 2020 [8] . As such, the findings suggest that the cumulative incidence of SARS-CoV-2 among TDA in Kenya was higher than in the general population and in other frontline workers.

Outside Kenya, some studies found 44%−45% seroprevalence of SARS-CoV-2 antibodies among HCWs, comparable to that among TDA in Kenya [9] [10] [11] . However, meta-analyses of studies globally estimated SARS-CoV-2 antibody prevalence among HCWs at 7% by July 2020 [12] and 9% by August 2020 [13] . Taken together, these data suggest that exposure to SARS-CoV-2 among TDA was higher than among HCWs in most settings.

To date, few studies have assessed SARS-CoV-2 antibody prevalence in nonhealthcare frontline workers. Seroprevalence was 38% seroprevalence among male migrant supermarket workers in Kuwait in May to June 2020 [14] . Elsewhere, however, seroprevalence among non-HCWs has been lower, ranging from 1% [15] to 22% [16] .

None of the NAT-positive TDA reported symptoms within 2 weeks of testing, suggesting predominantly asymptomatic COVID-19 among TDA. Although data on symptoms may have been subject to reporting bias, 93% of SARS-CoV-2 infections confirmed in Kenya by October 23, 2020 were asymptomatic [17] . The similarity in anti-SARS-CoV-2 antibody seropositivity among Kenyan and non-Kenyan TDA indicates predominantly occupation-related exposure to SARS-CoV-2. The fact that seroprevalence differed by sampling site suggests some heterogeneity in exposure risk.

Despite sampling at 3 different sites, we cannot be sure that the sample included are representative of all TDA in Kenya, or even those transiting through these sites. Participation in the serosurvey was voluntary, only half of those approached agreed to be sampled, and sociodemographic data for the target population are not available. However, data on county of residence for Kenyan TDA indicates representation from most counties. Seroprevalence estimates did not account for clustering by site or by driver-assistant pairs. The use of antibodies to estimate cumulative incidence of SARS-CoV-2 infection assumes universal seroconversion, minimal mortality, and antibody persistence. If these assumptions are incorrect-for example, there is evidence suggestive of antibody waning [18] [19] [20] -the cumulative incidence of infection would be underestimated. To minimize bias due to assay sensitivity and specificity, adjusted seroprevalence estimates were calculated.

These findings indicate substantial cumulative incidence of SARS-CoV-2 infection-most of which was asymptomaticamong TDA in Kenya, despite prevention measures. The occupational nature of haulage entails interaction with many contacts over large geographical areas; as such, TDA may unintentionally contribute to the spread of emerging infections. These findings illustrate the challenge of infection prevention within an occupational group whose role in sustaining supply chains remains vital during a pandemic. In addition, they underscore the importance of national and regional preparedness plans for the safe continuation of haulage in future pandemics.

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

We thank the following KEMRI-Wellcome Trust Research Programme teams: the COVID-19 Laboratory Team; the Pneumococcal Conjugate Vaccine Impact Study (PCVIS) team for supporting sample collection training, field supervision and data entry; the COVID-19 data team; and the Community Engagement team (Supplementary Table 4)

INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated program of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases (NIAID) Centres of Excellence for Influenza Research and Surveillance (CEIRS) (contract HHSN272201400008C). A. A. is funded by a Department for International Development (DFID)/Medical Research Council (MRC)/ National Institutes of Health Research (NIHR)/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1). J. A. G. S. is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation. I. M. O. A. is funded by the United Kingdom's MRC and DFID through an African Research Leader Fellowship (MR/S005293/1) and by the NIHR-Mucosal Pathogens Research Unit (MPRU) at UCL (Grant 2268427 LSHTM

EAC administrative guidelines to facilitate movement of good and services during the COVID-19 pandemic 2020

Update of coronavirus in the country and response measures, as at 7th

Protocol for control of COVID-19 at ground crossings and along the transport corridors

Estimated incidence of COVID-19 illness and hospitalization-United States

A serological assay to detect SARS-CoV-2 seroconversion in humans

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Seroprevalence of antibodies to SARS-CoV-2 among health care workers in Kenya

Crick COVID-19 Consortium; SAFER Investigators. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

Asymptomatic seroconversion of immunoglobulins to SARS-CoV-2 in a pediatric dialysis unit

SARS-CoV-2 seropositivity in asymptomatic frontline health workers in Ibadan, Nigeria

COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes

Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and metaanalysis

Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait

SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Šibenik-Knin County, Croatia

SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study

Ministry of Health Government of Kenya. COVID-19 outbreak in Kenya: Daily Situation Report. Nairobi: Ministry of Health Government of Kenya

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network-12 states

We thank the truck drivers and assistants for their participation. We thank the Busia Transporters Chairman for support in engaging truck drivers and assistants. We thank the Busia and Kilifi County Health Management Teams (CHMTs), Busia Port Health, Malaba Port Health, and Gongoni area salt companies for their support of this activity, including training support by Busia and Kilifi CHMT members. We thank the Director, KEMRI Centre

Potential conflicts of interest. R. A., M. M., K. K., and P. A. are from the Ministry of Health, Government of Kenya. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.